Background. Human immunodeficiency virus (HIV)-infected patients have weak responses to vaccines and may require revised immunization regimens. We investigated the safety and immunogenicity of 2 doses of hepatitis A virus (HAV) vaccine followed by a booster dose in HIV-infected children receiving stable highly active antiretroviral therapy.
infections [7] [8] [9] and to booster vaccination [10] [11] [12] . The latter response seems to be more variable [13] and depends on the degree of immunosuppression that patients had before HAART [2, 14, 15] . Less information is available on responses to neoantigens, in particular in the pediatric age group.
The objective of this study was to determine the immunogenicity and safety of hepatitis A virus (HAV) vaccine administered to children and adolescents with advanced HIV infection who recovered CD4 + T cell numbers while receiving HAART. The seroprevalence of HAV is !10% in children in the United States, which allowed us to surmise that HAV vaccine would function as a neoantigen for the majority of subjects eligible for this study.
SUBJECTS, MATERIALS, AND METHODS
Study population and design. HIV-infected subjects 2-21 years old were enrolled in this Pediatric AIDS Clinical Trials Group study. Local institutional review board approval and informed consent from subjects or their parents/guardians were obtained. Eligibility criteria included receipt of prophylaxis against Pneumocystis carinii pneumonia for at least 6 months, stable HAART, CD4 + T cell percentages у25% for subjects !6 years old and у20% for subjects 16 years old, absence of previous hepatitis A vaccination or wild-type disease, and no administration of immunoglobulin for 3 months before enrollment. At enrollment, prophylaxis against P. carinii pneumonia was discontinued. Subjects received the first dose of HAV vaccine at enrollment and a second dose 24 weeks later. The subgroup of subjects who consented to a third dose of HAV vaccine received it at week 104 or later. Doses were 720 and 1440 ELISA units of HAVRIX (Glaxo-SmithKline) for subjects !18 and у18 years old, respectively. T cell subsets and plasma HIV RNA were measured every 8 weeks. Subjects who developed opportunistic infections and those whose CD4 + T cell percentages decreased to !15% were allowed to discontinue the study.
Assay for anti-HAV antibodies. Anti-HAV antibody titers were measured using a quantitative ELISA. Precoated HAV microtiter plates (Viral Antigens) were incubated with serial dilutions of anti-HAV World Health Organization standards and 100 mL of serum samples diluted 1:21 in assay IgG diluent (Viral Antigens). After 1 h of incubation, plates were washed, and bound antibodies were revealed with alkaline phosphatase-conjugated goat anti-human IgG (ICN Pharmaceuticals) and pnitrophenyl phosphate chromogenic substrate (Sigma). The antibody titer of each sample was calculated by interpolating its corresponding optical density on the linear regression curve generated with the World Health Organization standards. This assay was validated using 20 serum samples from HAV-naive healthy volunteers and 10 serum samples with previously determined concentrations of anti-HAV antibody (gift from Dr. Paul Willems, GlaxoSmithKline Vaccine Division). Antibody titers у20 mIU/mL were considered to be protective against HAV infection and also defined HAV seropositive or immune status. Antibody responses were further classified as low if titers were !250 mIU/mL and high if titers were у250 mIU/ mL, on the basis of the observation that virtually all healthy persons immunized against HAV had antibody titers 1250 mIU/ mL at 4-8 weeks after the time when the last vaccine dose was administered. In addition, estimates of the durability of the protection conferred by the HAV vaccine were based on the magnitude of the antibody response after the last dose of the primary immunization and the decrease in antibody titers in healthy persons [16] .
Statistical methods. The x 2 test and Fisher's exact test were used to assess associations between characteristics of patients and anti-HAV antibody responses. Continuous variables were analyzed using 2-sample t, Kruskal-Wallis, and Wilcoxon tests. Pearson's correlation coefficient was used to assess linear associations, and, when indicated, Spearman's rank correlation coefficient was calculated. The paired t test was also used to assess within-subject variable changes between 2 periods, and McNemar's test was used to compare proportions between 2 periods. Two-sided was considered to be statistically P ! .05 significant. SAS statistical software (version 8.1; SAS Institute) was used for all analyses.
RESULTS
Clinical and demographic characteristics of the study population. Between September 1999 and June 2000, 235 eligible HIV-infected subjects were enrolled in the present study, including 152 who were HAV seronegative, 48 who were HAV seropositive, and 35 for whom baseline anti-HAV antibody titers were not measured (table 1). The median age at enrollment was 9 years, and there were approximately equal numbers of boys and girls. The ethnicity reflected the current demographic distribution of pediatric HIV-infected subjects in the United States, with about half of the subjects of African American origin. HAV-seronegative and HAV-seropositive subjects did not differ significantly with respect to age, sex, ethnicity, geographic location of residence (data not shown), or stage of HIV infection.
Of the 152 subjects who were HAV seronegative at baseline, 1 received a single dose of HAV vaccine and was excluded from the immunogenicity analysis. Of the 48 subjects who were HAV seropositive at baseline, 2 did not receive any doses of HAV vaccine and were excluded from both the immunogenicity and safety analyses, and an additional subject was excluded from the immunogenicity analysis because of missing week 32 antibody titer data. Hence, the immunogenicity and safety analyses were conducted on 196 and 233 subjects, respectively.
Immunogenicity of 2 doses of HAV vaccine administered to HAV-seronegative subjects. Anti-HAV antibody titers measured at week 32, which corresponded to 8 weeks after the time when the second vaccine dose was administered, showed that 146 subjects (97%) who were HAV seronegative at baseline seroconverted, and 5 subjects (3%) did not. The median antibody titer at week 32 was 320 mIU/mL (figure 1A). Only 80 subjects (53%) had antibody titers у250 mIU/mL at week 32 and met the definition of having a high antibody response. Factors that could potentially modulate the antibody response to the HAV vaccine were compared in subjects with high and low antibody responses (table 2) . Sex, race/ethnicity, age at enrollment, baseline CD4 + T cell percentage, history of having a CD4 + T cell percentage !15%, duration of time with CD4 + T cell percentage 115%, and week 32 plasma HIV RNA level did not significantly differ between the 2 groups. A higher proportion of subjects with high antibody responses had undetectable plasma HIV RNA at baseline than did those with low antibody responses (56% vs. 32%;
). In addition, P p .02 subjects with high antibody responses had higher median CD4 + T cell percentages than did those with low antibody responses at the time when the second vaccine dose was administered (33% vs. 30%;
). The correlation between the week 32 P p .03 antibody titer and the week 24 CD4
) further cor-0.16 P p .04 roborated this association. In contrast, there was no correlation between the increase in the CD4 + T cell percentage from week 0 to week 24 and antibody titers ( [Pearson's correr p 0.016 lation coefficient];
). P p .84 Persistence of anti-HAV antibodies after 2 doses of HAV vaccine in HAV-seronegative subjects. Antibody titers were measured 18 months after the time when the second vaccine dose was administered, at week 104. The decrease in antibody + T cell percentages у20% while receiving highly active antiretroviral therapy. Bars represent median antibody titers at the indicated time points for the whole group (total), subjects with antibody titers у250 mIU/mL at week 32 (high), and subjects with antibody titers !250 mIU/mL at week 32 (low). Arrows indicate the number of vaccine doses administered before each measurement. The time course is not plotted on a time scale. Antibody titers after the third vaccine dose were significantly higher than they were after the second vaccine dose ( ). B, Correlation between the magnitude of anti-HAV an-P p .001 tibody responses after 2 and 3 vaccine doses. Data were derived from 76 subjects. The relationship was significant: (Pearson's corr p 0.67 relation coefficient);
. P p .0001 titers over time, expressed as a percentage, was calculated for each subject by subtracting the value for the week 104 antibody titer from the value for the week 32 antibody titer, dividing by the value for the week 32 antibody titer, and multiplying by 100. In 120 HAV-seronegative subjects with week 104 antibody titer data, the median antibody titer was 97 mIU/mL, and the median decrease in specific antibodies was 74% ( figure 1A ). The decrease in antibody titers did not differ significantly between response category groups: a median decrease of 62% in subjects with low antibody responses (median antibody titer at week 104, 36 mIU/mL), compared with a median decrease of 79% in subjects with high antibody responses (median antibody titer at week 104, 126 mIU/mL).
Of the 120 subjects with week 104 antibody titer data, 108 (90%) had persisting protective antibody titers, whereas 12 (10%) did not. Of the latter group, 2 subjects had never mounted a protective response, 9 had week 32 antibody titers у20 to !250 mIU/mL, and 1 had a week 32 antibody titer of 329 mIU/mL. At 18 months after the time when the last vaccine dose was administered, subjects with low antibody responses after the 2-dose HAV vaccine regimen were less likely than those with high antibody responses to have an antibody titer у20 mIU/mL (P p .0003).
Antibody responses to a third dose of HAV vaccine in HAVseronegative subjects. A total of 76 HAV-seronegative subjects who received 3 doses of HAV vaccine and had antibody titers measured at all time points contributed data for this analysis. A comparison of the week 104 antibody titers, demographics, and HIV disease status (CD4 + T cell percentage and plasma HIV RNA level) did not show significant differences between subjects who did or did not receive the third vaccine dose. Eight weeks after the time when the third vaccine dose was administered, 74 subjects (97%) had protective antibody titers, including 58 subjects (76%) with antibody titers у250 mIU/ mL. Of the 2 subjects with antibody titers !20 mIU/mL after the second vaccine dose, 1 seroconverted and 1 did not after the third vaccine dose. Furthermore, the proportion of subjects with high antibody responses was significantly higher after the third vaccine dose than it was after the second vaccine dose ( ), and the median antibody titer was significantly P p .0002 higher after 3 vaccine doses than it was after 2 vaccine doses (602 vs. 287 mIU/mL; ) ( figure 1A ). P ! .0001 Analyses of correlations between antibody titers and several factors that could potentially affect the response to vaccination were performed. Age, sex, baseline or week 24 CD4 + T cell percentage, and week 104 plasma HIV RNA level were not significantly different between subjects with high and low antibody responses after the third vaccine dose. However, there was a trend associating higher antibody titers with higher CD4 + T cell percentages at the time when the third vaccine dose was administered ( [Pearson's correlation coefficient]; P p r p 0.16 .07). Antibody titers at week 112 were significantly higher in subjects with high antibody titers at week 32 ( [Pearr p 0.674 son's correlation coefficient]; ) (figure 1B), suggesting P p .0001 that the factors that determined the magnitude of the antibody response remained constant over ∼2.5 years of observation in these subjects.
Anamnestic antibody responses to HAV vaccine in HAVseropositive subjects. A total of 45 HAV-seropositive subjects received у2 vaccine doses and had antibody titers measured at week 32. The median antibody titer after the second vaccine dose was 517 mIU/mL (figure 2A). All 45 subjects had antibody titers higher than the protective threshold of 20 mIU/mL. In addition, 32 subjects (71%) had antibody titers у250 mIU/mL; among subjects who were HAV seropositive at baseline, the proportion with high antibody responses was significantly higher than that among subjects who were HAV seronegative at baseline (
). An analysis of factors that P p .04 could potentially modulate the recall antibody response of HAV-seropositive subjects (table 3), which was similar to the analysis performed for HAV-seronegative subjects, did not reveal any significant differences between subjects with high and + T cell percentages у20% while receiving highly active antiretroviral therapy. Bars represent median antibody titers at the indicated time points for the whole group (total), subjects with antibody titers у250 mIU/mL at week 32 (high), and subjects with antibody titers !250 mIU/mL at week 32 (low). Arrows indicate the number of vaccine doses administered before each measurement. The time course is not plotted on a time scale. Antibody titers after the third vaccine dose were significantly higher than they were after the second vaccine dose ( ). B, Correlation between the magnitude of anti-HAV antibody responses after 2 and P p .0001 3 vaccine doses administered to HAV-seropositive subjects. Data were derived from 26 HAV-seropositive, HIV-infected subjects who received 3 vaccine doses. ). There was a significantly higher pro-P p .34 portion of Hispanic subjects among those with low antibody responses than among those with high antibody responses (54% vs. 16%;
). The baseline CD4 + T cell percentage was P p .05 significantly higher in subjects with high antibody responses than in subjects with low antibody responses (33% vs. 28%;
). P p .03
Forty HAV-seropositive subjects who received у2 vaccine doses had week 104 antibody titer data. The median antibody titer was 242 mIU/mL overall, 65 mIU/mL in subjects with low antibody responses at week 32, and 251 mIU/mL in subjects with high antibody responses at week 32 ( figure 2A ). Thirtynine subjects (98%) had protective antibody titers, whereas 1 had a titer !20 mIU/mL. Persistence of protective antibody titers was significantly associated with higher week 32 antibody titers ( ). The proportion of subjects with protective P p .005 week 104 antibody titers did not differ between subjects who were HAV seropositive and subjects who were HAV seronegative at baseline ( ). P p .19 Of 26 subjects who were HAV seropositive at baseline and received a third vaccine dose, all had protective antibody titers, and 24 (92%) had antibody titers у250 mIU/mL. The median antibody titer after the third vaccine dose was 1031 mIU/mL (figure 2A), which was significantly higher than the median antibody titer of 603 mIU/mL measured in the same 26 subjects after the second vaccine dose ( ). Correlation analysis P p .003 of week 32 and week 112 antibody titers showed that there was a highly significant association (Spearman's rank correlation coefficient, ; ) (figure 2B). r p 0.50 P p .01 Safety of HAV vaccine. There were no grade 3 or 4 adverse events (definition available at: http://pactg.s-3.com/) related to the vaccine in 233 subjects who received у1 vaccine dose, irrespective of whether the subjects were HAV seronegative or HAV seropositive at baseline.
DISCUSSION
This study demonstrated that the standard 2-dose HAV vaccine regimen is safe in children with advanced HIV infection who had a CD4 + T cell percentage у20% while undergoing HAART. However, this vaccine regimen in children with HIV infection had decreased immunogenicity, particularly with respect to anti-HAV antibody titers, compared with results obtained in healthy children. In a previous study, this regimen induced a seroconversion rate of 100% in healthy children [15] , compared with 97% in our subjects. Furthermore, using an antibody quantitation method standardized against serum samples from previous studies, we established that the antibody titers generated by the vaccine in our subjects were 1-2 orders of magnitude lower than those in healthy persons. In previous studies, 100% of healthy children and adults vaccinated against HAV had antibody titers у250 mIU/mL 4-8 weeks after the last dose of vaccine, with geometric mean antibody titers of ∼3500 mIU/ mL [15] [16] [17] [18] [19] [20] . In contrast, only half of our subjects had comparable antibody titers. Although the rate of the decrease in anti-HAV antibody titers that was calculated in the present study was comparable to that previously reported in healthy persons [16, 21] , because the antibody response to the vaccine was lower in HIV-infected children, 10% of subjects in the present study lost protective antibody titers as early as 2 years after vaccination.
In the present study, a third dose of HAV vaccine was safe and generated significantly higher antibody titers than did the initial 2-dose regimen. In contrast to the observation that anti-HAV antibodies in normal hosts have been shown to interfere with the response to the HAV vaccine [13] , we did not observe a comparable inhibitory effect in HIV-infected children who were HAV seropositive as a result of vaccination or wild-type HAV infection. Furthermore, after the third vaccine dose, the antibody titers in HIV-infected children were of the same order of magnitude as those reported in healthy persons after the standard immunization regimen, and, therefore, it is tempting to speculate that the persistence of protective antibody titers after a 3-dose HAV vaccine regimen in HIV-infected children undergoing HAART might be similar to that in healthy hosts. A limitation of our data was that only half of the HAV-seronegative subjects received 3 doses of HAV vaccine. However, there were no significant differences between subjects who received 2 or 3 vaccine doses with respect to demographics, HIV disease characteristics, or antibody titers at week 104, which suggests that it might be acceptable to generalize these conclusions. Thus, the recommendation that emerges from this study is to increase the number of doses of HAV vaccine in the primary immunization schedule for HIV-infected children.
The results of the present study seem to compare favorably with reports of HAV vaccine immunogenicity in HIV-infected adults in both the pre-and post-HAART eras, in which the seroconversion rates were 73%-88% and 68%-94%, respectively [10, 22, 23] . Detailed comparisons are difficult to make, however, because these studies used varying immunogens, administration schedules, and definitions of seroconversion, and they sometimes differed from ours. A study of HAV vaccine immunogenicity performed in the pre-HAART era in HIV-infected subjects with hemophilia (predominantly children), found a seroconversion rate of 76% [24] , emphasizing the beneficial effect of HAART on immune responses to vaccines.
To understand the mechanisms that restricted the antibody response in our patient population and to further deduce the optimal conditions for immunizing HIV-infected children, we performed multiple correlation analyses, including age, sex, and characteristics of HIV infection as potential determining factors of the antibody response to the HAV vaccine. We found a weak but significant correlation between anti-HAV antibody titer and CD4 + T cell percentage, which suggested that HIV disease status might play a role in the attenuated antibody production. However, the correlation between antibody titer and CD4 + T cell percentage was weak ( [Pearson's correlation coeffir p 0.16 cient]), and the difference in CD4 + T cell percentages between subjects with high and low antibody responses (33% and 30%, respectively) was not of a clinically significant order of magnitude. There was a clear association between undetectable HIV RNA at baseline and high antibody response to the first vaccine dose, whereas HIV RNA level did not seem to affect anamnestic responses to the HAV vaccine. This confirms previous observations made about the administration of varicella vaccine to HIV-infected children [25] . Taken together, these data indicate that primary immunizations should be initiated at a time when HIV replication is under control, as demonstrated by undetectable plasma HIV RNA, in order to maximize immune responses. This observation has important implications for the optimal time to start therapy in HIV-infected children.
Our data did not show any correlation between anti-HAV antibody titer and classification in the past as being in Centers for Disease Control and Prevention (CDC) immunologic category 3. This finding was in contrast to the results of a study in which a decreased anamnestic response to tetanus vaccine was found in HIV-infected adults classified as being in CDC immunologic category 3 [11] . The difference in the responses to vaccines and other immune functions between HIV-infected adults and children [26] underscores the uniqueness of the immune system in children and the need to tailor immune therapies specifically for this age group.
In all subjects in the present study, a striking correlation was found between the magnitude of the antibody responses after the second and third vaccine doses. This correlation did not seem to reflect a merely additive phenomenon between newly generated antibodies and preexisting ones, because, in children who were HAV seropositive at baseline, there was no correlation between baseline antibody titers and subsequent ones. The correlation between antibody responses after 2 and 3 doses of HAV vaccine indicated that there was a regulatory mechanism restricting the antibody responses in our subjects that did not change over у2 years of stable HAART. Elucidating the mechanism that accounts for decreased immune responses in these patients seems extremely important for at least 2 reasons. First, in a previous study [27] , we showed that 10 (12%) of 85 subjects with low antibody responses developed serious bacterial infections, compared with only 5 (4%) of 113 subjects with high antibody responses ( , x 2 test). Second, this persistent P p .05 immune deficiency may compromise responses to other vaccines in the current immunization schedule or under development, including, possibly, a therapeutic HIV vaccine. Further studies to evaluate the CD4 + T helper cell function and the number and function of B cells, to enhance our understanding of immune reconstitution or lack thereof, and to provide strategies that will improve immune defenses in this patient population are being planned.
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